New cream hopes to stop scarring hair loss in its tracks
NCT ID NCT07487948
First seen Mar 27, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This study tests a cream called delgocitinib in 30 adults with two types of scarring hair loss (LPP and CCCA). The goal is to see if the cream is safe and can reduce inflammation that causes hair loss. Participants will apply the cream twice daily for 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.